Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
pieris pharmaceuticals的併購合作伙伴Palvella Therapeutics獲得了FDA孤兒產品開發辦公室高達260萬美元的補助金，用於QTORIN 3.9% 雷帕黴素無水凝膠用於微囊性淋巴管畸形的3期SELVA試驗。
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
pieris pharmaceuticals的併購合作伙伴Palvella Therapeutics獲得了FDA孤兒產品開發辦公室高達260萬美元的補助金，用於QTORIN 3.9% 雷帕黴素無水凝膠用於微囊性淋巴管畸形的3期SELVA試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。